Frank S Menniti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8432145/publications.pdf

Version: 2024-02-01

94	10,333	50566 48	46524 93
papers	citations	h-index	g-index

98	98	98	10856
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels. Pharmacological Reviews, 2021, 73, 1469-1658.	7.1	237
2	Modulating inhibitory response control through potentiation of GluN2D subunit-containing NMDA receptors. Neuropharmacology, 2020, 173, 107994.	2.0	5
3	PTC-174, a positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits. Neuropharmacology, 2020, 173, 107971.	2.0	13
4	PDE10A Inhibitorsâ€"Clinical Failure or Window Into Antipsychotic Drug Action?. Frontiers in Neuroscience, 2020, 14, 600178.	1.4	20
5	Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-Oxide. Frontiers in Neuroscience, 2019, 13, 837.	1.4	16
6	Identification of new PDE9A isoforms and how their expression andÂsubcellular compartmentalization in the brain change across the life span. Neurobiology of Aging, 2018, 65, 217-234.	1.5	30
7	Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1. Journal of Medicinal Chemistry, 2018, 61, 4635-4640.	2.9	19
8	NMDA Receptors in the Central Nervous System. Methods in Molecular Biology, 2017, 1677, 1-80.	0.4	105
9	N-Methyl-D-Aspartate Receptors, Ketamine, and Rett Syndrome: Something Special on the Road to Treatments?. Biological Psychiatry, 2016, 79, 710-712.	0.7	22
10	Structural Basis for Negative Allosteric Modulation of GluN2A-Containing NMDA Receptors. Neuron, 2016, 91, 1316-1329.	3.8	74
11	Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant Efficacy. Neuropsychopharmacology, 2016, 41, 1486-1494.	2.8	29
12	MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit. PLoS ONE, 2016, 11, e0148129.	1.1	45
13	Translational psychiatryâ€"light at the end of the tunnel. Annals of the New York Academy of Sciences, 2015, 1344, 1-11.	1.8	11
14	Phosphodiesterase 10A inhibitor MP-10 effects in primates: Comparison with risperidone and mechanistic implications. Neuropharmacology, 2014, 77, 257-267.	2.0	22
15	Small-molecule phosphodiesterase probes: discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1. MedChemComm, 2014, 5, 1290-1296.	3.5	31
16	Positive Allosteric Modulation of AMPA Receptors from Efficacy to Toxicity: The Interspecies Exposure-Response Continuum of the Novel Potentiator PF-4778574. Journal of Pharmacology and Experimental Therapeutics, 2013, 347, 212-224.	1.3	46
17	PDE4 as a target for cognition enhancement. Expert Opinion on Therapeutic Targets, 2013, 17, 1011-1027.	1.5	114
18	Assessment of adverse effects of neurotropic drugs in monkeys with the â€œDrug Effects on the Nervous Systemâ€•(DENS) scale. Journal of Neuroscience Methods, 2013, 215, 97-102.	1.3	7

#	Article	IF	Citations
19	Allosteric Modulators for the Treatment of Schizophrenia: Targeting Glutamatergic Networks. Current Topics in Medicinal Chemistry, 2013, 13, 26-54.	1.0	74
20	Phosphodiesterase 9A Regulates Central cGMP and Modulates Responses to Cholinergic and Monoaminergic Perturbation In Vivo. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 396-409.	1.3	73
21	A non-brain penetrant PDE5A inhibitor improves functional recovery after stroke in rats. Restorative Neurology and Neuroscience, 2012, 30, 283-289.	0.4	6
22	Application of Structure-Based Drug Design and Parallel Chemistry to Identify Selective, Brain Penetrant, In Vivo Active Phosphodiesterase 9A Inhibitors. Journal of Medicinal Chemistry, 2012, 55, 9055-9068.	2.9	50
23	Design and Discovery of 6-[(3S,4S)-4-Methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-py (PF-04447943), a Selective Brain Penetrant PDE9A Inhibitor for the Treatment of Cognitive Disorders. Journal of Medicinal Chemistry, 2012, 55, 9045-9054.	2.9	71
24	Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms. Neurobiology of Learning and Memory, 2012, 97, 370-379.	1.0	60
25	PDE Inhibition and cognition enhancement. Expert Opinion on Therapeutic Patents, 2012, 22, 349-354.	2.4	48
26	The distribution of phosphodiesterase 2A in the rat brain. Neuroscience, 2012, 226, 145-155.	1.1	55
27	Use of Structure-Based Design to Discover a Potent, Selective, In Vivo Active Phosphodiesterase 10A Inhibitor Lead Series for the Treatment of Schizophrenia. Journal of Medicinal Chemistry, 2011, 54, 4536-4547.	2.9	47
28	Phosphodiesterase Inhibition to Target the Synaptic Dysfunction in Alzheimerâ€™s Disease. Topics in Medicinal Chemistry, 2010, , 57-90.	0.4	11
29	Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction. Behavioural Brain Research, 2010, 212, 41-48.	1.2	46
30	Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10A. Neuropharmacology, 2010, 58, 444-451.	2.0	48
31	Glutamate Receptor Ion Channels: Structure, Regulation, and Function. Pharmacological Reviews, 2010, 62, 405-496.	7.1	2,973
32	Inhibition of the Striatal Specific Phosphodiesterase PDE10A Ameliorates Striatal and Cortical Pathology in R6/2 Mouse Model of Huntington's Disease. PLoS ONE, 2010, 5, e13417.	1.1	158
33	Cyclic GMP Signaling Is Involved in the Luteinizing Hormone-Dependent Meiotic Maturation of Mouse Oocytes1. Biology of Reproduction, 2009, 81, 595-604.	1.2	277
34	Phosphodiesterase 5A Inhibitors Improve Functional Recovery after Stroke in Rats: Optimized Dosing Regimen with Implications for Mechanism. Journal of Pharmacology and Experimental Therapeutics, 2009, 331, 842-850.	1.3	39
35	Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18225-18230.	3.3	144
36	Inhibition of Phosphodiesterase 10A Increases the Responsiveness of Striatal Projection Neurons to Cortical Stimulation. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 785-795.	1.3	119

#	Article	IF	Citations
37	Immunohistochemical Localization of Phosphodiesterase 2A in Multiple Mammalian Species. Journal of Histochemistry and Cytochemistry, 2009, 57, 933-949.	1.3	152
38	Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease. Neurobiology of Disease, 2009, 34, 450-456.	2.1	71
39	Potent and cellularly active 4-aminoimidazole inhibitors of cyclin-dependent kinase 5/p25 for the treatment of Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5703-5707.	1.0	40
40	Identification of a Brain Penetrant PDE9A Inhibitor Utilizing Prospective Design and Chemical Enablement as a Rapid Lead Optimization Strategy. Journal of Medicinal Chemistry, 2009, 52, 7946-7949.	2.9	67
41	Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1‹i›H‹/i›-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophreniaâ€Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1).. Journal of Medicinal Chemistry, 2009, 52, 5188-5196.	2.9	195
42	PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Current Opinion in Drug Discovery & Development, 2009, 12, 458-67.	1.9	16
43	Effects of a NR2B selective NMDA glutamate antagonist, CPâ€101,606, on dyskinesia and parkinsonism. Movement Disorders, 2008, 23, 1860-1866.	2.2	126
44	Synthesis of Novel Pyrrolo[3,4â€‹i›d‹/i›]pyrazoleâ€dicarboxylic Acids and Evaluation of Their Interaction with Glutamate Receptors. Chemistry and Biodiversity, 2008, 5, 657-663.	1.0	9
45	PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia. Schizophrenia Research, 2008, 101, 36-49.	1.1	120
46	Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 681-690.	1.3	268
47	Structural basis for the catalytic mechanism of human phosphodiesterase 9. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13309-13314.	3.3	60
48	An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive Disorder. Journal of Clinical Psychopharmacology, 2008, 28, 631-637.	0.7	453
49	Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2007, 323, 318-326.	1.3	97
50	The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101â€‰606 in rats and rhesus monkeys. Behavioural Pharmacology, 2007, 18, 731-743.	0.8	27
51	Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology, 2007, 52, 1509-1520.	2.0	45
52	Discovery of a Series of 6,7-Dimethoxy-4-pyrrolidylquinazoline PDE10A Inhibitorsâ€. Journal of Medicinal Chemistry, 2007, 50, 182-185.	2.9	113
53	Quantification of MPTP-induced dopaminergic neurodegeneration in the mouse substantia nigra by laser capture microdissection. Journal of Neuroscience Methods, 2007, 159, 291-299.	1.3	15
54	Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Current Opinion in Investigational Drugs, 2007, 8, 54-9.	2.3	65

#	Article	IF	Citations
55	Synthesis, Chiral Resolution, and Enantiopharmacology of a Potent 2,3-Benzodiazepine Derivative as Noncompetitive AMPA Receptor Antagonist. Journal of Medicinal Chemistry, 2006, 49, 575-581.	2.9	35
56	Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function. Neuropharmacology, 2006, 51, 374-385.	2.0	221
57	Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis. Neuropharmacology, 2006, 51, 386-396.	2.0	259
58	Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience, 2006, 139, 597-607.	1.1	186
59	Phosphodiesterases in the CNS: targets for drug development. Nature Reviews Drug Discovery, 2006, 5, 660-670.	21.5	353
60	New 7,8-ethylenedioxy-2,3-benzodiazepines as noncompetitive AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 167-170.	1.0	23
61	Immunohistochemical Localization of Phosphodiesterase 10A in Multiple Mammalian Species. Journal of Histochemistry and Cytochemistry, 2006, 54, 1205-1213.	1.3	244
62	Pde10a. , 2006, , .		1
63	Synthesis of 2-semicarbazonomethyl-4,5-methylenedioxyphenylacetic acids as anticonvulsant agents. Il Farmaco, 2005, 60, 231-235.	0.9	6
64	Molecular Mechanism of AMPA Receptor Noncompetitive Antagonism. Neuron, 2005, 48, 279-288.	3.8	101
65	1-Aryl-6,7-methylenedioxy-3H-quinazolin-4-ones as Anticonvulsant Agents.. ChemInform, 2004, 35, no.	0.1	0
66	Discovery and SAR of 2-aminothiazole inhibitors of cyclin-dependent kinase 5/p25 as a potential treatment for Alzheimerâ€™s disease. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5521-5525.	1.0	95
67	The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology, 2004, 188, 471-479.	2.0	88
68	NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology, 2004, 47, 184-194.	2.0	85
69	Synthesis of 5-substituted 7,9-dihydro-8H-[1,3]dioxolo[4,5-h][2,3]benzodiazepin-8-ones as anticonvulsant agents. Arkivoc, 2004, 2004, 196-203.	0.3	2
70	1-Aryl-6,7-methylenedioxy-3 H -quinazolin-4-ones as anticonvulsant agents. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 4427-4430.	1.0	59
71	Immunohistochemical localization of PDE10A in the rat brain. Brain Research, 2003, 985, 113-126.	1.1	320
72	Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms. European Journal of Pharmacology, 2003, 475, 29-35.	1.7	49

#	Article	IF	Citations
73	Characterization of the mechanism of anticonvulsant activity for a selected set of putative AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 443-446.	1.0	17
74	CP-465,022, a Selective Noncompetitive AMPA Receptor Antagonist, Blocks AMPA Receptors but Is Not Neuroprotective In Vivo. Stroke, 2003, 34, 171-176.	1.0	26
75	Repeated Estradiol Treatment Prevents MPTP-Induced Dopamine Depletion in Male Mice. Neuroendocrinology, 2003, 77, 223-231.	1.2	85
76	Functional characterization of CP-465,022, a selective, noncompetitive AMPA receptor antagonist. Neuropharmacology, 2002, 42, 143-153.	2.0	58
77	Quinazolin-4-one Î±-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonists:Â Structureâ^'Activity Relationship of the C-2 Side Chain Tether. Journal of Medicinal Chemistry, 2001, 44, 1710-1717.	2.9	43
78	Methaqualone derivatives are potent noncompetitive AMPA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1203-1205.	1.0	24
79	Characterization of the Binding Site for a Novel Class of Noncompetitive Î±-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptor Antagonists. Molecular Pharmacology, 2000, 58, 1310-1317.	1.0	49
80	Antiparkinsonian Actions of CP-101,606, an Antagonist of NR2B Subunit-Containing N-Methyl-d-Aspartate Receptors. Experimental Neurology, 2000, 163, 239-243.	2.0	124
81	CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents. Neuropharmacology, 2000, 39, 1147-1155.	2.0	51
82	CPâ€101,606: An NR2Bâ€Selective NMDA Receptor Antagonist. CNS Neuroscience & Therapeutics, 1998, 4, 307-322.	4.0	19
83	(3R,4S)-3-[4-(4-Fluorophenyl)-4-hydroxypiperidin-1-yl]chroman-4,7-diol:Â A Conformationally Restricted Analogue of the NR2B Subtype-Selective NMDA Antagonist (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol. Journal of Medicinal Chemistry, 1998, 41, 1172-1184.	2.9	32
84	CP-101,606, a potent neuroprotectant selective for forebrain neurons. European Journal of Pharmacology, 1997, 331, 117-126.	1.7	103
85	Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. British Journal of Pharmacology, 1997, 122, 809-812.	2.7	122
86	A short synthesis of GYKI 52466. Bioorganic and Medicinal Chemistry Letters, 1993, 3, 1991-1992.	1.0	6
87	Inositol phosphates and cell signaling: new views of InsP5 and InsP6. Trends in Biochemical Sciences, 1993, 18, 53-56.	3.7	136
88	Inositol polyphosphates and calcium signaling. Molecular and Cellular Neurosciences, 1992, 3, 1-10.	1.0	18
89	Role of Inositol Phosphates in the Actions of Substance P on NK1Receptors in Exocrine Gl and Cells. Annals of the New York Academy of Sciences, 1991, 632, 94-102.	1.8	16
90	Newly Synthesized Dopamine as the Precursor for Norepinephrine Synthesis in Bovine Adrenomedullary Chromaffin Cells. Journal of Neurochemistry, 1989, 53, 890-897.	2.1	13

#	Article	IF	Citations
91	Adrenomedullary Chromaffin Cells as a Model to Study the Neurobiology of Ascorbic Acid: From Monooxygenation to Neuromodulation. Annals of the New York Academy of Sciences, 1987, 498, 28-53.	1.8	38
92	Intracerebroventricular administration of oxytocin and maternal behavior in rats after prolonged and acute steroid pretreatment. Hormones and Behavior, 1983, 17, 45-53.	1.0	57
93	Differential effects of estrogen and androgen on locomotor activity induced in castrated male rats by amphetamine, a novel environment, or apomorphine. Brain Research, 1981, 216, 89-107.	1.1	60
94	Persistence of dihydrotestosterone inhibition of lordosis in estrogen-primed rats fed a tryptophan-deficient diet. Brain Research Bulletin, 1981, 7, 1-4.	1.4	5